Literature DB >> 24530747

Primary application of PPE68 of Mycobacterium tuberculosis.

Zhiling Dong1, Lei Xu1, Jing Yang1, Yonglin He1, Qian She1, Jingxian Wang1, Zhuangmiao Zhang1, Xin Feng1, Dairong Li2, Chun Yang3.   

Abstract

PPE68 protein is absent from BCG and the attenuated strains of Mycobacterium tuberculosis (MTB). In this study, the shuttle plasmid pBudCE4.1/PPE68/OriM was constructed and transformed into BCG to obtain PPE68 recombination BCG (PPE68-rBCG), and BALB/c mice were immunized with PPE68-rBCG to evaluate the immunological characterization of PPE68-rBCG. The level of lgG2a, IFN-γ, IL-12 and IL-4 in serum of immunized mice were detected, the proliferation response of spleen lymphocyte were measured, the frequency of CD4(+), CD8(+) and CD4(+)/CD8(+) were determined, and the spleen and lung tissue were prepared for pathological analysis. PPE68-rBCG was constructed successfully and could induce powerful Th1 immune response in mice. Besides, we took the purified recombination PPE68 (rPPE68) protein as diagnostic antigen to detect pulmonary tuberculosis patients (n=252) and extrapulmonary tuberculosis patients (n=66). We also used anti-PPE68 polyclonal antibody as coating antibody to detect specific antigen in the same serum samples. Our data provide an experimental basis for potential application of rPPE68 in the diagnosis of tuberculosis, especially for extrapulmonary tuberculosis.
Copyright © 2014 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24530747     DOI: 10.1016/j.humimm.2014.02.017

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  1 in total

1.  EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A.

Authors:  Yingchun Yan; Qing-Jie Xue; Ang Liu; Hui Wang; Honghua Zhang; Shuang Wang; Longyu Zhao; Yunqing Li; Xiuzhen Li; Yuanyuan Yang; Ting Chen; Shigen Li
Journal:  Hum Vaccin Immunother       Date:  2019-10-29       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.